EFFECTS OF LOVASTATIN THERAPY ON PLASMINOGEN-ACTIVATOR INHIBITOR-1 ANTIGEN LEVELS

被引：54
|
作者：
ISAACSOHN, JL
SETARO, JF
NICHOLAS, C
DAVEY, JA
DIOTALEVI, LJ
CHRISTIANSON, DS
LISKOV, E
STEIN, EA
BLACK, HR
机构：
[1] YALE UNIV,CTR CARDIOVASC DIS PREVENT,NEW HAVEN,CT
[2] MED RES LABS,CINCINNATI,OH
来源：
AMERICAN JOURNAL OF CARDIOLOGY | 1994年 / 74卷 / 07期
关键词：
D O I：
10.1016/0002-9149(94)90322-0
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
There are now extensive data suggesting that the progression of atherosclerosis can be altered by cholesterol-lowering therapy. The changes in stenosis severity, measured angiographically, are small relative to the clinical benefit noted. Other factors, in addition to changes in stenosis severity, are probably operative. Effects of cholesterol-lowering on endothelial function, perhaps mediated by reductions in PAI-1 levels, may be one of these mechanisms. This uncontrolled study requires further investigation to elucidate the independent relation between lovastatin, PAI-1, and fibrinogen. © 1994.
引用
下载
收藏
页码：735 / 737
页数：3
相关论文
共 50 条
  • [41] BIOLOGICAL EFFECTS OF DISRUPTION OF THE TISSUE-TYPE PLASMINOGEN-ACTIVATOR, UROKINASE-TYPE PLASMINOGEN-ACTIVATOR, AND PLASMINOGEN-ACTIVATOR INHIBITOR-1 GENES IN MICE
    CARMELIET, P
    BOUCHE, A
    DECLERCQ, C
    JANSSEN, S
    POLLEFEYT, S
    WYNS, S
    MULLIGAN, RC
    COLLEN, D
    ATHEROSCLEROSIS III: RECENT ADVANCES IN ATHEROSCLEROSIS RESEARCH: THE THIRD SARATOGA INTERNATIONAL CONFERENCE ON ATHEROSCLEROSIS IN NEKOMA, 1995, 748 : 367 - 382
  • [42] STUDIES ON PLASMINOGEN-ACTIVATOR INHIBITOR-1 LEVELS IN HUMAN BREAST-CANCER
    REILLY, D
    ANDRESEASEN, P
    DUFFY, MJ
    BIOCHEMICAL SOCIETY TRANSACTIONS, 1990, 18 (02) : 354 - 355
  • [43] INDEPENDENT REGULATION OF PLASMINOGEN-ACTIVATOR INHIBITOR-2 AND PLASMINOGEN-ACTIVATOR INHIBITOR-1 IN HUMAN SYNOVIAL FIBROBLASTS
    HAMILTON, JA
    CHEUNG, D
    FILONZI, EL
    PICCOLI, DS
    WOJTA, J
    GALLICHIO, M
    MCGRATH, K
    LAST, K
    ARTHRITIS AND RHEUMATISM, 1992, 35 (12): : 1526 - 1534
  • [44] RELATIONSHIPS BETWEEN EUGLOBULIN CLOT LYSIS TIME AND THE PLASMA-LEVELS OF TISSUE PLASMINOGEN-ACTIVATOR AND PLASMINOGEN-ACTIVATOR INHIBITOR-1
    URANO, T
    SAKAKIBARA, K
    RYDZEWSKI, A
    URANO, S
    TAKADA, Y
    TAKADA, A
    THROMBOSIS AND HAEMOSTASIS, 1990, 63 (01) : 82 - 86
  • [45] THE INHIBITION OF TISSUE-TYPE PLASMINOGEN-ACTIVATOR BY PLASMINOGEN-ACTIVATOR INHIBITOR-1 - THE EFFECTS OF FIBRINOGEN, HEPARIN, VITRONECTIN, AND LIPOPROTEIN(A)
    EDELBERG, JM
    REILLY, CF
    PIZZO, SV
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1991, 266 (12) : 7488 - 7493
  • [46] REVERSIBLE INTERACTIONS BETWEEN PLASMINOGEN ACTIVATORS AND PLASMINOGEN-ACTIVATOR INHIBITOR-1
    MIMURO, J
    KANEKO, M
    MURAKAMI, T
    MATSUDA, M
    SAKATA, Y
    BIOCHIMICA ET BIOPHYSICA ACTA, 1992, 1160 (03) : 325 - 334
  • [47] STABILITY OF PLASMINOGEN-ACTIVATOR INHIBITOR-1 (PAI-1)
    LINDAHL, TL
    SIGURDARDOTTIR, O
    WIMAN, B
    THROMBOSIS AND HAEMOSTASIS, 1989, 62 (02) : 748 - 751
  • [48] EFFECT OF PEPTIDES ON THE INACTIVATION OF TISSUE PLASMINOGEN-ACTIVATOR BY PLASMINOGEN-ACTIVATOR INHIBITOR-1 AND ON THE BINDING OF TISSUE PLASMINOGEN-ACTIVATOR TO ENDOTHELIAL-CELLS
    WITTWER, AJ
    SANZO, MA
    THROMBOSIS AND HAEMOSTASIS, 1990, 64 (02) : 270 - 275
  • [49] ELISA SYSTEMS FOR ACTIVE AND TOTAL PLASMINOGEN-ACTIVATOR INHIBITOR-1 (PAI-1) ANTIGEN
    RESCH, I
    KRUTISCH, G
    GEIGER, M
    BINDER, BR
    THROMBOSIS AND HAEMOSTASIS, 1989, 62 (01) : 299 - 299
  • [50] GENE INACTIVATION OF TISSUE-TYPE PLASMINOGEN-ACTIVATOR, UROKINASE-TYPE PLASMINOGEN-ACTIVATOR AND PLASMINOGEN-ACTIVATOR INHIBITOR-1 IN MICE
    CARMELIET, P
    SCHOONJANS, L
    STASSEN, JM
    KIECKENS, L
    VANNUFFELEN, A
    DEMOL, M
    COLLEN, D
    MULLIGAN, R
    THROMBOSIS AND HAEMOSTASIS, 1993, 69 (06) : 764 - 764
12345